ClinicalTrials.gg
CompletedNCT04227990Updated Jan 18, 2020

Plinabulin iv Solution in Prevention of TAC Induced Neutropenia

A Phase 2 interventional study of Plinabulin and Pegfilgrastim in Chemotherapy-induced Neutropenia, sponsored by BeyondSpring Pharmaceuticals Inc.. Completed at 11 sites in 2 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-01-18.

Sponsored by BeyondSpring Pharmaceuticals Inc. · Phase 2, Interventional, and Supportive care

From the registry’s dates

  • Primary completion was Oct 2018, 8 years 1 month ago, and no results have been posted to the registry.
  • Registered 2 years 1 month after the study started (first participant enrolled Nov 2017, registered Jan 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
115
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 33 studies testing pegfilgrastim in Neutropenia — none open to participants now, none under way, none of them phase 3. pegfilgrastim · Neutropenia.

Enrollment
16th of 28
115 · median 121
Started
2017
with 2 others
Phase 2
14 of 33
none open now
Registered
32nd of 33
by date
Lead sponsor
1 of 33
BeyondSpring Pharmaceuticals Inc.

Among the 33 studies testing pegfilgrastim in Neutropenia, this one is the 16th largest by enrollment of the 28 interventional ones that give a count, is one of 3 that started in 2017, is one of 14 in phase 2, and was the 32nd registered.

Neutropenia

316 studies on the registry are indexed under Neutropenia; 42 are open to participants now.

Browse Neutropenia studies →

Open to participants now

None of the 33 studies testing pegfilgrastim in Neutropenia is open now. The open studies under Neutropenia, anywhere →

About pegfilgrastim

pegfilgrastim: first FDA approval 2002 (NEULASTA), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 24 Neutropenia studies recruiting now, 12 (50%) set no upper age limit and 12 (50%) stop at 75 or younger; 11 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 33 studies testing pegfilgrastim in Neutropenia as a file.
02

Study summary

The primary purpose of this study is to compare the duration of severe neutropenia (DSN) in patients treated with: Docetaxel, doxorubicin, and cyclophosphamide (TAC) + pegfilgrastim versus Docetaxel, doxorubicin, and cyclophosphamide (TAC) + monotheray plinabulin or combination plinabulin/pegfilgrastim Severe neutropenia is an absolute neutrophil count (ANC) \<0.5 × 10\^9/L. Docetaxel, doxorubicin, and cyclophosphamide (TAC) will be used as the chemotherapy in this study.

Read the detailed description

This is a multi-center randomized study, Phase 2 study. 115 patients were enrolled in Phase 2. Two regimens were evaluated in Phase 2: a plinabulin monotherapy regimen and a combination therapy regimen of plinabulin + pegfilgrastim. The monotherapy regimen includes 4 arms: pegfilgrastim 6.0 mg alone; and 10, 20, or 30 mg/m2 plinabulin.

The combination regimen includes 4 arms: pegfilgrastim 6.0 mg alone; and 20 mg/m2 plinabulin + pegfilgrastim 1.5, 3, or 6.0 mg. The pegfilgrastim 6.0 mg alone arm is the control arm for comparison with the monotherapy and combination therapy arms for the interim evaluation.

The purpose of this study is to compare the duration of severe neutropenia (DSN) in patients with early stage (Stage I and II) and Stage III breast cancer (node positive or node negative with high risk of recurrence) receiving docetaxel, doxorubicin, and cyclophosphamide (TAC) and monotherapy plinabulin or combination therapy plinabulin/pegfilgrastim. Severe neutropenia is an absolute neutrophil count (ANC) \<0.5 × 10\^9/L.

Docetaxel, doxorubicin, and cyclophosphamide (TAC) were used as the chemotherapy in this study. These agents are among the most active and commonly used chemotherapeutic agents employed for treating patients with breast carcinoma.

In particular, TAC chemotherapy has been used for the adjuvant treatment of HER2 negative early breast cancer patients with node positive disease as well as for node negative breast cancer patients who have a high risk of recurrence.

Plinabulin is a novel small molecule that is being developed for the mitigation of chemotherapy-induced neutropenia. Administered by IV infusion on the same day of (approximately 1 hour after) chemotherapy (TAC), plinabulin was given in a single dose per cycle. Plinabulin is being studied to see if it is a convenient alternative to G-CSF, pegfilgrastim, for the prevention of chemotherapy-induced neutropenia.

64 patients were enrolled for monotherapy evaluation and 51 patients were enrolled for the combination therapy Arm 5, 6 and 7 for efficacy and safety evaluation. The arm designation and planned intervention is as follows:

For monotherapy:

Arm 1: TAC + pegfilgrastim (6.0 mg)

Arm 2: TAC + plinabulin (10 mg/m2).

Arm 3: TAC + plinabulin (20 mg/m2).

Arm 4: TAC + plinabulin (30 mg/m2).

For combination therapy:

Arm 1: TAC + pegfilgrastim (6.0 mg)

Arm 5: TAC + plinabulin (20 mg/m2) + pegfilgrastim (1.5 mg)

Arm 6: TAC + plinabulin (20 mg/m2) + pegfilgrastim (3.0 mg)

Arm 7: TAC + plinabulin (20 mg/m2) + pegfilgrastim (6.0 mg)

Cycles 1 to 4 will consist of TAC (or TC for Cycles 2 to 4) administered IV on Day 1, every 21 days. Patients in Arms 2, 3 and 4 will receive a single dose of plinabulin, 30 minutes after the end of the TAC (or TC for Cycles 2 to 4) infusion on Day 1. The plinabulin dose will be infused over 30 minutes (±5 minutes) in Arms 2 and 3 and over 60 minutes (±5 minutes) in Arm 4 (in order to improve tolerability at the higher 30 mg/m2 dose level).

On Day 2 of each cycle (≥24 hours after completing chemotherapy) patients in Arm 1 and in combination therapy will receive a single dose of pegfilgrastim (1.5, 3.0, or 6.0 mg) (subcutaneous injection).

03

Conditions studied

  • Chemotherapy-induced Neutropenia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Women who are at least 18 years of age at the time of signing the form.
  2. In the opinion of their treating oncology investigator, are candidates for at least 4 cycles of chemotherapy with TAC (docetaxel, doxorubicin, and cyclophosphamide).
  3. Patients who are candidates for adjuvant or TAC will meet all of the following criteria:

    proven, early stage (Stage I and II) and Stage III breast cancer, and Are within 60 days of a diagnostic or surgical procedure (biopsy, umpectomy, mastectomy), and Have had no prior chemotherapy.

  4. Pathological confirmation of cancer is required.
  5. (ECOG) performance status of 0 or 1.
  6. Have of 3 months or more.
  7. The following laboratory results provided by the central laboratory within 14 days prior to study drug administration:

    ≥ 1.5 x 10\^9/L independent of growth factor support; ≥ 9 g/dL independent of transfusion or growth factor support; calculated (CLcr) ≥ 60 mL/min using Cockcroft-Gault formula; Serum total ≤ (ULN); (AST) and alanine aminotransferase (ALT) as 2.5 x ULN (≤ 1.5 x ULN if alkaline phosphate is > 2.5 x ULN).

  8. (PT) and International Normalized Ratio (INR) ≤1.5 × ULN, activated partial thromboplastin time (PTT) ≤1.5 × ULN, based on central laboratory results.
  9. Women of have a negative pregnancy test at screening. Women of childbearing potential are defined as sexually mature women without prior hysterectomy or who have had any evidence of menses in the past 12 months. However, women who have been amenorrhoeic for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, anti-estrogens, or ovarian suppression.

Women of childbearing potential (i.e., menstruating women) must have a negative urine pregnancy test (positive urine tests are to be confirmed by serum test) documented within the 24-hour period prior to the first dose of study drug.

Sexually active women of childbearing potential enrolled in the study must agree to use two forms of accepted methods of during the course of the study and for 3 months after their last dose of study drug. Effective birth control includes (a) intrauterine device plus one barrier method; (b) on stable doses of hormonal contraception for at least 3 months (e.g., oral, injectable, implant, transdermal) plus one barrier method; (c) 2 barrier methods. Effective barrier methods are male or female condoms, diaphragms, and spermicides (creams or gels that contain a chemical to kill sperm); or (d) a vasectomized partner.

Exclusion criteria

Exclusion Criteria:

  1. History of myelogenous leukemia, myelodysplastic syndrome, or sickle cell disease.
  2. Use of strong , CYP2D6 or P-glycoprotein (P-gp) inhibitors and inducers, within 14 days of the first administration of study drug and for the duration of the study.
  3. Received an agent or tumor vaccine within 2 weeks before the first dose of study drug; patients must have recovered from toxicity of prior treatment and have no >Grade 1 (CTCAE) (v4.03) treatment emergent adverse events (TEAE).
  4. Receiving any concurrent anticancer therapies (including concomitant anti-/neu agents such as trastuzumab [Herceptin], trastuzumab emtansine [TDM-1, Kadcyla®], pertuzumab [Perjeta®], lapatinib [Tykerb®]).
  5. Received a prior bone marrow or stem cell transplant.
  6. Have a co-existing active infection or received systemic anti-infective treatment within 72 hours before the first dose of study drug.
  7. Concurrent or prior radiation therapy within 4 weeks before the first dose of study drug.
  8. Chronic use of filgrastim, pegfilgrastim, or any bioequivalent (biosimilar) for severe chronic neutropenia or other chronic neutropenia syndrome.
  9. Presence of any serious or uncontrolled illness including, but not limited to: uncontrolled diabetes, ongoing or active infection, symptomatic congestive heart failure unstable angina pectoris, uncontrolled cardiac arrhythmia, uncontrolled arterial thrombosis, symptomatic pulmonary embolism, and psychiatric illness that would limit compliance with study requirements or any other conditions that would preclude the patient from study treatment as per the discretion of the Investigator.
  10. Significant prior doxorubicin (>240 mg/m2) or anthracycline exposure that would preclude the safe administration of TAC chemotherapy as described in the protocol.
  11. Significant cardiovascular history:

    Cardiac ventricular dysfunction inhibiting the patient"s ability to receive 4 cycles of doxorubicin.

    History of myocardial infarction or ischemic heart disease within 1 year (within a window of up to 18 days less than 1 year) before first study drug administration Uncontrolled arrhythmia History of congenital (ECG) findings consistent with active ischemic heart disease Class III or IV cardiac disease; Uncontrolled hypertension: blood pressure consistently >150 mm Hg systolic and > 100 mm Hg diastolic in spite of antihypertensive medication

  12. History of hemorrhagic diarrhea, inflammatory bowel disease, or active uncontrolled peptic ulcer disease. (Concomitant therapy with ranitidine or its equivalent and/or omeprazole or its equivalent is acceptable). History of ileus or other significant gastrointestinal disorder known to predispose to ileus or chronic bowel hypomotility.
  13. Any other active requiring active therapy.
  14. Known (HIV) seropositivity.
  15. Active virus (HBV) infection which requires antiviral treatment or the patient has detectable Hepatitis B surface Antigen (HBsAg); hepatitis B surface antibody (anti-HBs) without detectable HBsAg does not exclude patients from the study. infection (Hepatitis C antibody reactive) which requires treatment also excludes patients from the study.
  16. Female patient who is pregnant or lactating.
  17. Use of prophylactic antibiotics.
  18. Unwilling or unable to comply with procedures required in this protocol.
  19. History of allergy to any of the study drugs.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
115 participants (actual)

Study arms

  • Active comparator
    TAC + Pegfilgrastim (6 mg)

    Drug: Pegfilgrastim · Drug: Docetaxel, doxorubicin, and cyclophosphamide (TAC)

  • Experimental
    TAC + Plinabulin 10 mg/m^2

    Drug: Plinabulin · Drug: Docetaxel, doxorubicin, and cyclophosphamide (TAC)

  • Experimental
    TAC + Plinabulin 20 mg/m^2

    Drug: Plinabulin · Drug: Docetaxel, doxorubicin, and cyclophosphamide (TAC)

  • Experimental
    TAC + Plinabulin 30 mg/m^2

    Drug: Plinabulin · Drug: Docetaxel, doxorubicin, and cyclophosphamide (TAC)

  • Experimental
    TAC + Pegfilgrastim (1.5 mg) + Plinabulin (20 mg/m^2)

    Drug: Plinabulin · Drug: Pegfilgrastim · Drug: Docetaxel, doxorubicin, and cyclophosphamide (TAC)

  • Experimental
    TAC + Pegfilgrastim (3 mg) + Plinabulin (20 mg/m^2)

    Drug: Plinabulin · Drug: Pegfilgrastim · Drug: Docetaxel, doxorubicin, and cyclophosphamide (TAC)

  • Experimental
    TAC + Pegfilgrastim (6 mg) + Plinabulin (20 mg/m^2)

    Drug: Plinabulin · Drug: Pegfilgrastim · Drug: Docetaxel, doxorubicin, and cyclophosphamide (TAC)

Interventions

  • Plinabulin (BPI-2358) is a synthetic, low molecular weight, new chemical entity that belongs to the diketopiperazine class of compounds. Plinabulin is intended for intravenous (IV) infusion and is diluted in D5W and administered for 30 minutes (± 5 minutes).

  • Pegfilgrastim is a long-acting granulocyte colony-stimulating factor that stimulates the growth of neutrophils, to reduce the incidence of fever and infection in patients with certain types of cancer who are receiving chemotherapy that affects the bone marrow.

    Also known as: Neulasta

  • DrugDocetaxel, doxorubicin, and cyclophosphamide (TAC)

    Docetaxel is a type of chemotherapy medicine called an taxane. Doxorubicin is a type of chemotherapy medicine called an anthracycline. Cyclophosphamide is a type of chemotherapy medicine called an alkylating agent.

06

What researchers measure

Primary outcomes

  1. Duration of Severe Neutropenia (DSN)

    Days with Severe Neutropenia in treatment Cycle 1

    Time frame: Cycle 1 (21 days)

Secondary outcomes

  1. Frequency of Grade 4 neutropenia

    Frequency of patients with at least 1 day of Grade 4 neutropenia (ANC \<0.5 × 109/L)

    Time frame: Cycle 1 (21 days)

  2. Bone pain score

    Mean pain score from the patient bone pain scale from pre-dose Day 1 to Day 8 in Cycle 1 (0-10 scale, higher score means worse outcome)

    Time frame: Cycle 1 (21 days)

  3. Change in bone pain score

    Change in bone pain score from pre-dose Day 1 through Day 8 in Cycle1 (0-10 scale, higher score means worse outcome)

    Time frame: Cycle 1 (21 days)

  4. Adverse events

    Incidences, occurrences, and severity of AEs/SAEs Cycle 1-4

    Time frame: Cycle 1 - 4 (21-day cycle)

07

Study locations

11 sites
  • Cancer Center of Guangzhou Medical University Breast Oncology
    Guangzhou, Guangzhou 510000, China
  • Harbin Medical University Cancer Hospital
    Harbin, Harbin 150000, China
  • Fourth Hospital of Hebei Medical University Breast cancer department
    Shijiazhuang, Hebei 500000, China
  • China-Japan Union Hospital of Jilin University Tumor department of Hematology
    Changchun, Jilin 130000, China
  • Liaoning Cancer Hospital & Institute
    Shenyang, Shenyang 110000, China
  • Dnipropetrovsk City Multifunctional Hospital #4 Oncology Department
    Dnepropetrovsk, 49102, Ukraine
  • Prykarpatskiy Regional Oncological Center
    Ivano-Frankivs'k, 76000, Ukraine
  • "V.T. Zaycev Institute of General and Urgent Surgery NAMS of Ukraine Dept. of Oncology
    Kharkiv, 61103, Ukraine
  • Public Institution Kryvyi Rih Oncology Center
    Krivoy Bereg, 50048, Ukraine
  • Kirovograd Regional Oncological Center
    Kropyvnytskyi, 25011, Ukraine
  • Odessa regional clinical hospital Thoracic Surgery Department Academician Zabolotnoho
    Odessa, 65025, Ukraine
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Oct 2018, 10 months.

Of 25 phase 2 interventional studies under Neutropenia, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 41. This study's 10 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2020
First posted
Jan 14, 2020
StartActual
Nov 27, 2017
Primary completionActual
Oct 15, 2018
CompletionActual
Jan 3, 2019
Last update
Jan 18, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 18, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04227990
Lead sponsor
BeyondSpring Pharmaceuticals Inc.
Responsible party
Sponsor
First posted
Jan 14, 2020
Start date
Nov 27, 2017
Primary completion
Oct 15, 2018
Completion
Jan 3, 2019
Last update
Jan 18, 2020

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: NPI 2358 · Pegfilgrastim

Start the discussion